LNAI experienced catastrophic financial deterioration with stockholders' equity collapsing from $132M to negative $21.3M while simultaneously acquiring a third subsidiary and pivoting business focus.
The company is now technically insolvent with negative equity of $21.3M, indicating severe financial distress that threatens business continuity. Despite this crisis, management expanded operations by acquiring BioSymetrics and shifted strategic focus away from HIV treatment toward molecular diagnostics, suggesting either a desperate pivot or poor capital allocation during a liquidity crisis.
LNAI's financial position deteriorated catastrophically with total assets plummeting 95% from $163M to $8.2M, stockholders' equity turning deeply negative at -$21.3M, and cash reserves falling 58% to just $93K. While gross profit improved marginally to $37K and operating cash flow losses decreased 28%, massive operating losses of $189M (vs. $81.6M prior year) and net losses of $178M completely overwhelmed any operational improvements. The company now faces immediate insolvency risk with minimal cash and negative equity, despite reducing R&D spending by 80%.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Capital expenditure jumped 136.5% — major investment cycle underway; assess returns on deployment.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 120.7% — review whether driven by operations, interest costs, or non-recurring items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 95% — asset sales, write-downs, or balance sheet optimization underway.
R&D spending cut 80.2% — could signal cost discipline or concerning reduction in innovation investment.
Cash declined 58% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 47.6% — monitor working capital adequacy and short-term liquidity.
Operating cash flow grew 28.2% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →